Einzeltreffer — DigiBib

The invention relates to producing medicinal agents for treating diabetes. There is proposed a method for producing a pharmaceutical composition containing insulin on a polysaccharide carrier, which involves mixing initial ingredients, wherein there is provided, for mixing, supplying positively charged chitosan sol with pH of 3.5 to 4.5 and negatively charged zinc free insulin, which is taken in the form of a colloidal solution or in the form of nanosized crystalline particles, bringing the pH of the mixed sol to a value of 5.5 to 6.5, producing a gel and dehydrating the produced gel to obtain solid particles, the size of which ranges from 10 to 100 mkm. The method makes it possible to produce a stable controlled release insulin-containing composition for peroral administration

Titel:	PHARMACEUTICAL COMPOSITION AND A METHOD FOR THE PRODUCTION THEREOF
Autor/in / Beteiligte Person:	NOGA, David Anatol'evich ; MATVIEEV, Pavel Gueorguievich ; MARKIN, Serguei Serqueevich ; BERENSHTEIN, Dmitrij Borisovich ; SIEMIENOV, Mikhail Pietrovich ; TARASOV, Alexandr Andreevich ; TARASOVA, Ol'ga Maratovna ; RED'KIN, Igor Viacheslavovich
Link:	View record in USPTO Patent Applications (Volltext)
Veröffentlichung:	2011
Medientyp:	Patent
Sonstiges:	Nachgewiesen in: USPTO Patent Applications Sprachen: English Document Number: 20110064818 Publication Date: March 17, 2011 Appl. No: 12/883984 Application Filed: September 16, 2010 Claim: 1. A method for producing a pharmaceutical composition comprising: providing insulin on a polysaccharide carrier and mixing mixing initial ingredients; supplying, for mixing, positively charged chitosan sol with pH of 3.5 to 4.5 and negatively charged zinc free insulin, which is taken in the form of a colloidal solution or in the form of nanosized crystalline particles; bringing the pH of the mixed sol to a value of 5.5 to 6.5; producing a gel and dehydrating the gel to obtain solid particles, the size of which ranges from 10 to 100 mkm. Claim: 2. The method according to claim 1, wherein the gel is produced at a presence of sodium alginate in the mixed sol in the amount not exceeding 5% of masses, if calculated per solid substance. Claim: 3. The method according to claim 1, further comprising mixing the initial ingredients based on the results of calculation of an insulin-chitosan mass ratio in the mixed sol to be equal to (0.2-0.8):1 under a condition of the mixed sol electrical neutrality. Claim: 4. The method according to claim 1, further comprising supplying for mixing positively charged chitosan sol in a buffered acetate solution with the size of chitosan particles of 200 to 400 nanometers. Claim: 5. The method according to claim 1, further comprising supplying for mixing positively charged chitosan sol in the form of its chlorohydrate having molecular mass of 80 to 120 kDa and deacetylation degree of 85 to 89%. Claim: 6. The method according to claim 1, further comprising supplying for mixing the insulin in the form of crystalline particles, the sizes of which are ranged from 800 to 1200 nanometers. Claim: 7. The method according to claim 1, further comprising supplying for mixing a colloidal solution of insulin in the phosphatic buffer with pH of 8.0 to 9.0. Claim: 8. The method according to claim 1, further comprising supplying for mixing chromatographically cleaned gene-engineered insulin obtained with the use of STRAIN ESCHERICHIA COLI XLI-BLUE/PINSR as PREPROINSULIN PRODUCENT. Claim: 9. A pharmaceutical composition of slowed down release for peroral administration comprising insulin on a carrier-chitosan, wherein the pharmaceutical composition is obtained using the method comprising providing insulin on a polysaccharide carrier and mixing mixing initial ingredients; supplying, for mixing, positively charged chitosan sol with pH of 3.5 to 4.5 and negatively charged zinc free insulin, which is taken in the form of a colloidal solution or in the form of nanosized crystalline particles; bringing the pH of the mixed sol to a value of 5.5 to 6.5; producing a gel and dehydrating the gel to obtain solid particles, the size of which ranges from 10 to 100 mkm. Claim: 10. The pharmaceutical composition of claim 9, wherein the gel is produced at a presence of sodium alginate in the mixed sol in the amount not exceeding 5% of masses, if calculated per solid substance. Claim: 11. The pharmaceutical composition of claim 9, wherein mixing the initial ingredients occurs based on the results of calculation of an insulin-chitosan mass ratio in the mixed sol to be equal to (0.2-0.8):1 under a condition of the mixed sol electrical neutrality. Claim: 12. The pharmaceutical composition of claim 9, further supplying for mixing positively charged chitosan sol in a buffered acetate solution with the size of chitosan particles of 200 to 400 nanometers. Claim: 13. The pharmaceutical composition of claim 9, further supplying for mixing positively charged chitosan sol in the form of its chlorohydrate having molecular mass of 80 to 120 kDa and deacetylation degree of 85 to 89%. Claim: 14. The pharmaceutical composition of claim 9, further supplying for mixing the insulin in the form of crystalline particles, the sizes of which are ranged from 800 to 1200 nanometers. Claim: 15. The pharmaceutical composition of claim 9, further supplying for mixing a colloidal solution of insulin in the phosphatic buffer with pH of 8.0 to 9.0. Claim: 16. The pharmaceutical composition of claim 9, further supplying for mixing chromatographically cleaned gene-engineered insulin obtained with the use of STRAIN ESCHERICHIA COLI XLI-BLUE/PINSR as PREPROINSULIN PRODUCENT. Current U.S. Class: 424/499 Current International Class: 61; 61; 82

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

PHARMACEUTICAL COMPOSITION AND A METHOD FOR THE PRODUCTION THEREOF